Search General Info
Search Education
Search Partnering Companies
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
NIBEC is established as a spin-off venture from Seoul National University, South Korea at 2004 and listed in Korean Stock Market (KOSDAQ) at 2011. The company's main technology is based on target-oriented peptide therapeutic discovery (TOPscovery) platform for drug discovery, delivery, and development. The company’s focus of therapeutic area includes inflammatory bowel disease (IBD), pulmonary fibrosis and oncology with well-defined mode of action. The peptide assets for both IBD and pulmonary fibrosis treatment have been in global phase I study, now in preparation of phase II study. In addition to the therapeutic peptide asset, NIBEC has drug delivery platforms; 1) target tissue/cell penetrating peptide carrier specialized for the delivery to the brain (BBB shuttle) or cancer and 2) oral peptide/protein delivery formulation. In addition to the drug development, the company already has entered the regenerative market using tissue engineering biomaterials.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1515842-1-JPG.jpg)
Ticker:
138610
Exchange:
KOSDOQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2004
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
Peptide therapeutics for the treatment of Inflammatory Bowel Disease (NIPEP-IBD)
Peptide therapeutics for the treatment of Pulmonary Fibrosis (NIPEP-PF)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-PARKY.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved